Literature DB >> 34392924

Immune PET Imaging.

Osigbemhe Iyalomhe1, Michael D Farwell2.   

Abstract

Fluorodeoxyglucose (FDG) PET/CT is sensitive to metabolic, immune-related, and structural changes that can occur in tumors in cancer immunotherapy. Unique mechanisms of immune checkpoint inhibitors (ICIs) occasionally make response evaluation challenging, because tumors and inflammatory changes are both FDG avid. These response patterns and sequelae of ICI immunotherapy, such as immune-related adverse events, are discussed. Immune-specific PET imaging probes at preclinical stage or in early clinical trials, which may help guide clinical management of cancer patients treated with immunotherapy and likely have applications outside of oncology for other diseases in which the immune system plays a role, are reviewed.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FDG; Immune imaging; Immune-related adverse events; Immunotherapy; PET/CT

Mesh：

Substances：

Year:  2021        PMID： 34392924      PMCID： PMC8371717          DOI： 10.1016/j.rcl.2021.05.010

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN： 0033-8389            Impact factor:   1.947


  98 in total

1.  Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.

Authors:  Helmut Huber; Marina Hodolic; Ingrid Stelzmüller; Rainer Wunn; Margit Hatzl; Franz Fellner; Bernd Lamprecht; Domenico Rubello; Patrick M Colletti; Michael Gabriel
Journal:  Nucl Med Commun       Date:  2015-05       Impact factor: 1.690

Review 2.  The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.

Authors:  Annie N M Wong; Grant A McArthur; Michael S Hofman; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-07       Impact factor: 9.236

3.  Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.

Authors:  Jennifer J Kwak; Sree Harsha Tirumani; Annick D Van den Abbeele; Phillip J Koo; Heather A Jacene
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

4.  Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer.

Authors:  Marc C Huisman; Anna-Larissa N Niemeijer; Albert D Windhorst; Robert C Schuit; David Leung; Wendy Hayes; Alex Poot; Idris Bahce; Teodora Radonic; Daniela E Oprea-Lager; Otto S Hoekstra; Erik Thunnissen; N Harry Hendrikse; Egbert F Smit; Adrianus J de Langen; Ronald Boellaard
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 10.057

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Authors:  Anna Maria Di Giacomo; Riccardo Danielli; Massimo Guidoboni; Luana Calabrò; Dora Carlucci; Clelia Miracco; Luca Volterrani; Maria Antonietta Mazzei; Maurizio Biagioli; Maresa Altomonte; Michele Maio
Journal:  Cancer Immunol Immunother       Date:  2009-01-13       Impact factor: 6.968

7.  Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

Authors:  Benjamin Y Kong; Alexander M Menzies; Catherine A B Saunders; Elizabeth Liniker; Sangeetha Ramanujam; Alex Guminski; Richard F Kefford; Georgina V Long; Matteo S Carlino
Journal:  Pigment Cell Melanoma Res       Date:  2016-08-04       Impact factor: 4.693

8.  Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.

Authors:  Tomomi Nobashi; Lucia Baratto; Sunil A Reddy; Sandhya Srinivas; Akira Toriihara; Negin Hatami; Thomas K Yohannan; Erik Mittra
Journal:  Clin Nucl Med       Date:  2019-04       Impact factor: 7.794

9.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Authors:  Philippe Armand; Andreas Engert; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John M Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Margaret A Shipp; Kazunobu Kato; Anne Sumbul; Benedetto Farsaci; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.